As seen on the 24/7 Wall St. homepage on November 13, 2026.
A second straight record close for the valve maker at $107.19, 1.3% above Thursday's peak. Medtronic rose 1.88% and Abbott 1.22% the same day, so the medtech bid was broad.
Moves: Nov 13, 2026 · Alpha Vantage daily close
Sponsored
43 stocks notched fresh 52-week highs this week, with leadership spread across Motorola Solutions, ICICI Bank, Edwards Lifesciences, Coca-Cola, Humana and Fastenal. Motorola Solutions leads at $530.42, 7.7% past its prior peak.
69 stocks printed fresh 52-week highs this week, with Regeneron clearing its prior peak by 14% at $904.35. Cheniere Energy, ICICI Bank, Grainger and Berkshire Hathaway also made the list.
The first full quarter of the slimmed down MedTech company beat on both lines, and management guided fiscal 2027 adjusted EPS to $13.10 to $13.30 against $12.70 last year. Free cash flow jumped 42.5%, the tell that the Life Sciences spin is paying off.
A 4.38% day adds roughly $2.4 billion to a $57 billion medtech name that rarely moves like this. Whether the $209.08 level holds into the next session is the thing to watch.
Medtronic just set a fresh 52-week high at $105.02, 2.97% above its prior peak from November 2025. The medtech giant has erased a spring slide that took it under $74.
Mitral and tricuspid therapy sales jumped 44.3% year over year, enough for management to lift full-year sales growth guidance and adjusted EPS targets. The structural heart franchise is widening its lead on a crowding field.
We delivered strong third-quarter growth of 11.2% which exceeded expectations, with broad-based performance across our businesses and regions, giving us the confidence to raise our full-year outlook.
A guidance raise from the structural heart leader lands while Abbott and Boston Scientific push harder into valve repair, and the growth came from every business and region. The $57 billion medtech name is defending share.
A 4.13% move to $208.57 adds roughly $2.3 billion to a $56.8 billion medtech name that rarely travels this far in a single session. Worth seeing whether it holds into the close.
A 4.57% climb to $104.81 adds roughly $6 billion to a $134.1 billion medical-device giant, and megacaps this size rarely move that far in a single session. Keep an eye on whether it holds above the $100.23 open.
Edwards Lifesciences cleared its July 6 ceiling by a hair at $95.20, a fresh 52-week high for the $54.8 billion heart valve maker. The stock has climbed back from $78 in February without a new peak until now.
The call is that falling long rates are repricing everything outside tech right now rather than earnings, and Cramer says growth stocks away from semis are the clean way to play it. He is warning Apple holders that guidance will disappoint even after a record quarter, and he is openly annoyed at Oracle for raising capital immediately after promising restraint.